Acumen Pharmaceuticals In... (ABOS)
NASDAQ: ABOS
· Real-Time Price · USD
1.42
0.02 (1.43%)
At close: Aug 15, 2025, 3:59 PM
1.45
2.11%
After-hours: Aug 15, 2025, 07:52 PM EDT
Acumen Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -40.95M | -28.8M | -37.15M | -29.77M | -20.54M | -14.87M | -16.5M | -12.96M | -11.61M | -11.31M | -12.87M | -10.71M | -10.15M | -9.13M | -8.35M | -3.9M | -61.36M | -27M |
Depreciation & Amortization | -658K | 45K | 44K | 45K | 45K | 44K | 39K | 40K | 53K | 52K | 49K | 44K | 39K | 37K | 3K | 1K | n/a | n/a |
Stock-Based Compensation | 2.5M | 2.47M | 2.34M | 2.34M | 2.47M | 2.48M | 1.63M | 1.6M | 1.52M | 1.39M | 888K | 840K | 715K | 618K | 365K | 304K | 127K | 126K |
Other Working Capital | 5.23M | -2.77M | 4.92M | 5.59M | 2.64M | -5.77M | 6.04M | -216K | -2.6M | 902K | 1.26M | 36K | 2.3M | -162K | 3.37M | -3.19M | -1.33M | 897K |
Other Non-Cash Items | 1M | -482K | -669K | -948K | -2.29M | -1.45M | 456K | -710K | -300K | -334K | -88K | 191K | 168K | 216K | 136K | -5K | 57.94M | 23.22M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 134K | n/a | n/a | n/a |
Change in Working Capital | 6.28M | -7.36M | 8.22M | 3.73M | 3.77M | -4.07M | 6.05M | -878K | -1.33M | 24K | 814K | 452K | 2.76M | -41K | 4.07M | -4.08M | -973K | 1.28M |
Operating Cash Flow | -31.83M | -34.12M | -27.21M | -24.6M | -16.55M | -17.86M | -8.31M | -12.9M | -11.67M | -10.18M | -11.2M | -9.18M | -6.47M | -8.3M | -3.64M | -7.69M | -4.26M | -2.37M |
Capital Expenditures | -9K | -79K | n/a | n/a | -5K | -11K | -14K | -7K | n/a | n/a | -35K | -81K | -36K | -9K | -26K | -8K | -6K | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3K | n/a | n/a | 20.39K | n/a | -8.82K | n/a | -94.09M | n/a | n/a | n/a |
Purchase of Investments | -3.01M | -35.05M | -15.1M | -98.54M | -11.8M | -45.29M | -71.78M | -126.73M | n/a | -52.13M | -29.39M | n/a | -3.04M | -9.09M | -9.98M | -94.09M | n/a | n/a |
Sales Maturities Of Investments | 41.5M | 63.82M | 44.76M | 88.41M | 49.51M | 36.1M | 22.98M | 34.73M | 11.06M | 10.2M | 9M | 56M | 11.86M | 4M | -104.08M | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -41.93K | -20.39K | 56K | 8.82K | -5.09M | 198.18M | -94.09M | n/a | n/a |
Investing Cash Flow | 38.48M | 28.69M | 29.66M | -10.13M | 37.7M | -9.2M | -48.81M | -92M | 11.06M | -41.93M | -20.42M | 55.92M | 8.79M | -5.1M | -10.01M | -94.1M | -6K | n/a |
Debt Repayment | n/a | n/a | -739K | n/a | n/a | -739K | 29.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | -73K | -9K | n/a | n/a | -32K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 37K | 739K | n/a | n/a | -60K | n/a | n/a | -145K | n/a | 392K | -263K | -14K | n/a | 13K | 168.78M | 1.64M | n/a |
Financial Cash Flow | n/a | -36K | -9K | -42K | -128K | 7.11M | 29.13M | 122.76M | -145K | n/a | 4.18M | -263K | -14K | n/a | 10K | 168.78M | 31.68M | n/a |
Net Cash Flow | 6.65M | -5.47M | 2.44M | -34.77M | 21.03M | -19.95M | -27.99M | 17.86M | -751K | -52.1M | -27.44M | 46.47M | 2.3M | -13.4M | -13.64M | 66.99M | 27.41M | -2.37M |
Free Cash Flow | -31.84M | -34.2M | -27.21M | -24.6M | -16.55M | -17.87M | -8.33M | -12.91M | -11.67M | -10.18M | -11.24M | -9.26M | -6.5M | -8.31M | -3.67M | -7.7M | -4.27M | -2.37M |